EGFR and cancer: Indeed, amplification of wild‐type EGFR was reported to decrease the sensitivity of EGFR‐mutated cancer cells to third‐generation EGFR‐TKIs in vitro31, 38, 39 and to cause resistance to osimertinib in a patient with T790M‐positive NSCLC.40